Virbac, one of the world’s leading companies in animal health, is continuing its expansion in Europe.
In addition to the recent finalization of the creation of its Irish subsidiary, Virbac announces the acquisition of its historical distributor in the Czech Republic and Slovakia, which becomes its 35th subsidiary.
This development strategy strengthens the group’s position in the European market for animal health.
Present in the Czech Republic and Slovakia since 2000 through its historical distributor, Virbac is well aware of these two markets, mainly oriented towards pets and ruminants.
In order to continue the development of its activities in this region and strengthen its presence in Central Europe, Virbac has acquired GS Partners, one of its oldest distributors in this area. This acquisition crowns the excellent work done for years by the teams of Jakub Satrapa, its former owner and future CEO of the Virbac subsidiary.
The new Virbac subsidiary in Ireland and the acquisition of GS Partners in the Czech Republic and Slovakia will allow the group to respond more broadly and quickly to the health needs of animals in these countries. Therefore, this development strategy strengthens Virbac’s position in the European animal health market, where the group continues to grow and expand.
Healthtech & Biotech News – Nice Côte d’Azur France
- Exceptional dynamics in the first half of 2024 for Virbac
- Virbac announces changes in its executive management
- Virbac finalizes acquisition of minority stake in Globion, Indian poultry vaccine specialist.
- Christophe Mossé appointed as CEO of Arkopharma group
- Nucleate France UniCA strengthens the ties between research, industry, and entrepreneurship in life sciences.
- Business Landing Nice Côte d’Azur: Support for business set up in France
- Biotyks sets up in Nice to develop its solution for managing irritable bowel syndrome
- The Climate and Biodiversity Tour in Nice
- Team Nice Côte d’Azur in force at Viva Tech 2024
- Entrepreneurship in Research Award 2024
